The Hindu·2 min read·medium
Pfizer's prostate cancer drug combination gets U.S. FDA priority review
R
Reuters
✦AI Summary
The U.S. FDA has granted priority review to Pfizer's application for a combination prostate cancer treatment using Talzenna and Xtandi. The treatment targets patients with metastatic castration-sensitive prostate cancer who have specific HRR gene mutations.
Pfizer said on Wednesday the U.S. Food and Drug Administration has granted priority review to its application seeking expanded approval for its prostate cancer treatment combination.
healthbusinessscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in